肝细胞癌四种临床分期系统预后判断和治疗指导价值的比较

目的 比较4个分期系统[巴塞罗那临床肝癌分期标准(BCLC)、日本综合分期积分(JIS)、意大利肝癌评分(CLIP)和国内分期]对中国肝癌患者预后判断和对治疗方案选择的指导意义.方法 回顾性分析2001年至2002年复旦大学附属中山医院收治的861例初发肝细胞癌患者的临床资料,分别按4个分期系统分期或评分,比较各期患者的生存情况以及不同治疗方案对其生存的影响.结果 在判断预后方面,BCLC、JIS和国内分期系统的各分期间生存率差异均有统计学意义;而在CLIP分期的一些评分间的生存率差异无统计学意义.在指导治疗方面,BCLC C期,CLIP 3、4分以及国内分期ⅢA期的患者接受手术治疗与接受肝动脉化学治疗栓塞(TACE)和(或)肝动脉栓塞(TAE)治疗的生存率差异无统计学意义;而比这些更早期的患者接受手术治疗的生存率优于接受TACE和(或)TAE治疗的生存率.结论 BCLC、JIS和国内分期系统在判断预后方面适用于中国患者;但仅国内分期和BCLC分期同时兼备了判断预后和指导治疗两方面的作用.     

肿瘤切除前TACE对巴塞罗那临床肝癌分期B期患者预后的影响

目的探讨肿瘤切除术前行经皮股动脉穿刺肝动脉化疗栓塞术（TACE）对巴塞罗那临床肝癌（BCLC）分期B期患者预后的影响。方法对309例首次行肝癌切除术的BCLC分期B期患者的临床资料进行回顾性分析,根据术前是否行TACE分为联合组和手术组,用两独立样本t检验和PearsonX2检验比较两组一般临床资料,用Log—rank检验和Cox比例风险回归模型比较两组生存率。结果两组一般临床资料无统计学差异（P〉0．05）;联合组和手术组中位生存期分别为36、26个月,组间比较P〈0．05（X2=9．226）;治疗方式、肿瘤直径、手术切缘和血清AFP水平是影响患者生存率的危险因素（P〈0．05）,且治疗方式是影响患者预后的独立危险因素（RR为1．576,95％CI为1．157—2．146,P=0．004）。结论对于BCLC分期B期患者,在切除术前给予辅助性TACE治疗有望延长术后生存时间。     

微血管侵犯分级对肝细胞癌行根治性肝切除术后早期复发的预测价值

目的回顾性分析肝细胞癌术后患者的预后,研究微血管侵犯(MVI)分级与经典临床肿瘤分期(TNM分期、BCLC分级)在肝细胞癌术后早期复发预测价值上的差异,进而探讨MVI分级的临床价值。方法选取2015年12月-2017年12月在昆明医科大学第二附属医院肝胆外科进行根治性肝切除术治疗的HCC患者共100例,根据随访2年后的结果,分为复发组(n=49)和未复发组(n=51)。比较2组患者的实验室指标及MVI分级情况;比较MVI分级、TNM分期和BCLC分级在预测患者术后2年无复发生存期的价值。符合正态分布计量资料2组间比较采用t检验;不符合正态分布的计量资料2组间比较采用Mann-Whitney U检验。计数资料2组间非等级资料比较采用χ2检验,等级资料比较采用Mann-Whitney U检验; 3组间比较采用Kruskai-Wallis H检验,进一步两两比较采用Bonferroni法。Kaplan-Meier法绘制生存曲线,log-rank检验进行比较。通过rms包计算一致性指数进行各临床病理分期预测价值的比较。结果与未复发组比较,复发组患者AFP水平更高(Z=0.099,P0.05)、发生MVI更多(Z=-2.651,P=0.008)。随访2年后,100例患者中M0组47例,M1组34例,M2组19例。M0级复发18例(38.3%),M1级复发16例(47.1%),M2级复发15例(78.9%),3组间复发情况比较差异有统计学意义(H=8.934,P=0.011),进一步两两比较,M2级患者复发比例均高于M0级和M1级(P值均0.05)。MVI分级为M0+M1患者累计复发率41.9%,M2患者累计复发率78.9%,2组比较差异有统计学意义(χ2=11.445,P0.001),M2级2年RFS较M0+M1级减少; BCLC分级为早期(0期+1期)患者累计复发率36.2%,中晚期(2期+3期)累计复发率66.7%,2组比较差异有统计学意义(χ2=5.047,P=0.012),中晚期组2年RFS较早期组减少; TNM分期为I期的患者累计复发率24.5%,Ⅱ+Ⅲ期累计复发率72.5%,2组比较差异有统计学意义(χ2=17.223,P0.001),Ⅱ+Ⅲ期组2年RFS较Ⅰ期组减少。在2年无复发生存期的预测价值上,TNM分期的预测价值最高,而MVI与BCLC的预测价值则差别较小(一致性指数:0.659 vs 0.598 vs 0.600)。结论相较于无风险及低风险的MVI患者,高风险MVI的患者在早期复发的几率显著上升,MVI或许可作为术后治疗的评估指标。     

不同分期系统对肝动脉化学治疗栓塞术治疗原发性肝癌预后评价作用的初步研究

分期是评估肿瘤的重要手段,能够指导治疗和判断预后.现今已经存在许多原发性肝癌的分期系统,但对这些分期的作用还存在很大争议.同时,肝动脉化学治疗栓塞术(transarterial chemoembolization,TACE)作为无法手术切除肝癌的主要治疗手段之一,关于各分期系统在其中应用的研究少见[1].本研究通过比较几种常用的分期系统,包括Child-Turcotte-Pugh(CTP)分级、Okuda分期、巴塞罗那临床肝癌(Barcelona clinic liver cancer,BCLC)分级、国内(CS)分期、法国(French)评分系统、意大利肝癌协作组(the cancer ofliver Italian program,CLIP)评分,探索肝癌TACE术后患者预后评价的有效分期,以期为治疗提供帮助.     

肝活喜片配合肝动脉化疗栓塞治疗Ⅱ、Ⅲ期原发性肝癌的临床研究

目的：观察肝活喜片配合肝动脉化疗栓塞（TACE）治疗Ⅱ、Ⅲ期原发性肝癌的临床疗效。探讨中、西医结合治疗Ⅱ、Ⅲ期肝癌的有效方法。方法：采用双盲法随机选取62例Ⅱ、Ⅲ期原发性肝癌患者用肝活喜片配合TACE治疗,并与31例使用肝复乐片配合TACE治疗的患者作对照。结果：两组疗效比较,治疗后症状积分,近期疗效及半年生存率均有显著性差异（P＜0．05）。1年、2年生存率均无显著性差异（P＞0．05）。结论：肝活喜儿配合TACE是治疗Ⅱ、Ⅲ期发性肝癌的理想方法。     

临床常用分期标准对原发性肝癌术后三年生存率的预测价值比较

目的 评价目前主要的4种肝癌分期标准CLIP评分,TNM、BCLC、Okuda分期对手术治疗后肝癌患者短期疗效的预测价值,选出不同临床阶段中的最优分期标准.方法 研究对象随机选自2003年3月到2008年7月在我院肝胆外科手术治疗的原发性肝癌患者,使用线性趋势卡方检验和似然比卡方检验评估各分期标准的同质性,使用COX比例风险模型计算了不同分期分别从模型中剔除时其相应对数似然估计值(-2 Loglikelihood)的升高大小.结果 患者1、2、3年总体生存率分别为84.7％、64.1％、42.9％,中位生存时间31个月,在4种评分标准中,CLIP评分和BCLC分期在同质性、判别力、梯度单一性和对模型预后预测价值的独立因素大小比较中要高于TNM和Okuda分期.结论 CLIP评分、BCLC分期对肝癌切除术后的预测价值优于TNM、Okuda分期.     

肝动脉化疗栓塞术治疗原发性肝癌疗效及影响因素

目的探讨肝动脉化疗栓塞术（TACE）治疗原发性肝癌的预后相关因素。方法回顾性分析150例TACE治疗原发性肝癌的临床资料,随访生存期,对可能的影响因素进行多因素分析。结果 1年、2年和3年生存率分别为56%、32.7%、22.7%,中位生存期为13个月;单因素分析显示预后相关因素包括BCLC分期、Child-Pugh分级、门静脉癌栓、肿瘤病灶类型、肿瘤累计直径、碘油沉积类型;多因素分析与预后相关的有统计学意义的因素有BCLC分期、Child-Pugh分级、碘油沉积类型。结论 TACE术前相关因素的评估对预测疗效有重要意义。     

BCLC分期C期肝细胞癌不同治疗方案的效果及预后影响因素分析

目的分析巴塞罗那肝癌临床分期(BCLC)C期肝细胞癌(HCC)的不同治疗方案及预后影响因素。方法回顾性分析2005年1月-2012年12月在广西医科大学附属肿瘤医院首次诊断并治疗的BCLC C期HCC患者的临床资料。按照治疗方案分为:单纯经肝动脉化疗栓塞术(TACE)组(n=20)、TACE+索拉非尼组(n=18)、TACE+消融组(n=17)、手术+TACE组(n=20)、手术+TACE+消融组(n=16)。随访并记录患者生存状况及具体死亡时间,比较各组生存期。计数资料组间比较采用χ2检验,计量资料组间比较采用方差分析;采用Kaplan-Meier绘制总生存率曲线,采用log-rank比较累积生存率,采用Cox回归模型行单因素、多因素分析。结果共纳入HCC患者91例,随访终止日期为2016年11月1日,随访率为100%。单因素分析结果显示,年龄、肝外转移、肿块类型、肿瘤最大直径、治疗方案等是BCLC C期HCC预后的影响因素(P值均0.05)。多因素结果显示,年龄(P=0.019)、肿瘤最大直径(P=0.018)、肝外转移(P=0.026)、治疗方案(P=0.006)是HCC预后的独立影响因素。不同方案治疗的BCLC C期HCC患者总生存期差异有统计学意义(χ2=22.841,P0.001)。其中,手术+TACE+消融组总生存期明显高于其他4组(P值均0.05);TACE+消融组总生存期明显高于单纯TACE组、TACE+索拉非尼组(P值均0.05);手术+TACE组的总生存期明显高于单纯TACE组、TACE+索拉非尼组(P值均0.05)。结论年龄、肿瘤最大直径、肝外转移、治疗方案是影响BCLC C期HCC预后的独立影响因素。可切除的BCLC C期HCC应首选手术治疗,术后予TACE预防复发;复发后病灶继续予TACE或消融治疗,若有机会可再次行外科切除;不可手术切除的BCLC C期HCC首选TACE联合消融治疗,二者可优势互补,提高总生存期。     

70例海南三亚黎族原发性肝癌患者个体化治疗远期疗效及预后的相关因素

目的:探讨三亚地区黎族原发性肝癌患者个体化综合治疗的疗效及预后的相关因素.方法:回顾性分析70例经个体化综合治疗的三亚地区黎族原发性肝癌患者的临床资料,全部原发性肝癌患者均为三亚地区黎族患者,采取以手术、介入栓塞化疗(transcatheter arterial chemoembolization,TACE)、分子靶向治疗、局部消融治疗以及中药扶正等综合治疗,观察个体化治疗后疗效及预后,分析相关因素.结果:70例患者中位生存期为9 mo.单因素分析结果显示:BCLC分期为0-B期、接受TACE术、接受手术、甲胎蛋白200 ng/mL、无合并肝硬化、Child-Pugh分级为A级、有局部消融治疗和分子靶向药物治疗与预后相关有统计学意义(P0.05).多因素分析显示:无合并肝硬化(P=0.012)、Child-Pugh分级为A级(P=0.000)、有接受手术(P=0.020)及BCLC分期为0-B期(P=0.006)为影响三亚地区黎族原发性肝癌患者综合治疗后远期疗效的保护因素.结论:三亚地区黎族原发性肝癌患者经手术、TACE、分子靶向治疗、局部消融治疗等综合治疗获得了较长的生存时间,早期发现和早期接受手术治疗以及较好的肝功能状态等综合治疗仍然为三亚地区黎族原发性肝癌患者有效的治疗模式.     

经肝动脉化疗栓塞术与肝切除术治疗巴塞罗那B期多发性肝细胞癌的近远期效果比较

目的对比研究经肝动脉化疗栓塞术(TACE)与肝切除术治疗巴塞罗那临床肝癌(BCLC)分期B期的多发性肝细胞癌(HCC)的近远期疗效。方法回顾性分析2010年6月-2011年6月在武汉市中心医院接受治疗的80例BCLC B期多发性HCC患者的临床资料,其中,49例行肝切除术(LR组),31例行TACE(TACE组)。比较2组患者术后并发症、肝功能变化、生存时间及生存率。计量资料2组间比较采用t检验;计数资料2组间比较采用χ~2检验。采用Kaplan-Meier曲线进行生存分析,进一步比较采用log-rank检验。结果术后1周,LR组和TACE组的TBil、ALT、AST均较术前显著升高(LR组:t值分别为3.181、2.181、2.955,P值分别为0.002、0.032、0.004;TACE组:t值分别为3.109、3.965、4.519,P值分别为0.003、0.001、0.001),且术后LR组的AST及ALT显著低于TACE组(t值分别为2.094、2.111,P值分别为0.040、0.038)。LR组的1、3、5年生存率分别为75.51%、51.02%、40.82%,显著高于TACE组的61.29%、22.58%、9.68%(P值均0.05);LR组的中位生存时间为36.3个月,明显长于TACE组的26.5个月(P0.05)。LR组的复发率显著低于TACE组(30.61%vs 67.74%,χ~2=10.576,P=0.001)。结论肝切除术治疗BCLC期多发性HCC的疗效优于TACE,可提高患者总生存率并延长生存时间。     

Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma

BACKGROUND: The long-term prognosis of hepatocellular carcinoma (HCC) remains poor and the prediction of survival is often difficult because of the limited liver function and frequent recurrence of HCC in most patients. Therefore, a prognostic classification of HCC should account for both tumor-related variables and liver function. METHODS: The value of reported prognostic factors for HCC was assessed and a new prognostic classification was established called the 'SLiDe' scoring system (S, stage; Li, liver damage; De, des-gamma-carboxy prothrombin) using 'stage' and 'liver damage' of the recently revised 4th edition of the Japanese staging system edited by the Liver Cancer Study Group of Japan, and the serum level of des-gamma-carboxy prothrombin (DCP) in 177 patients with HCC. RESULTS: Univariate analysis identified Child-Pugh stage, liver damage, tumor morphology, portal vein thrombosis, stage, serum level of alpha-fetoprotein (AFP), serum level of DCP, and initial treatment as significant prognostic factors. Of these, liver damage, stage, and serum level of DCP remained independent predictive factors of survival after multivariate prognostic analysis using the proportional hazards regression model. Therefore, a new prognostic scoring system (SLiDe scoring system) was derived that assigned a linear score (0/1/2/3) to these three covariates. This SLiDe scoring system was statistically a better model for predicting outcome in the present study population than the Cancer of the Liver Italian Program (CLIP) and the Japan Integrated Staging (JIS) scoring systems, as judged by the Akaike Information Criteria. CONCLUSION: The SLiDe scoring system is useful for the assessment of the prognosis of patients with HCC as long as the Japanese staging system is used, although this uses parameters such as the indocyanine green retention test and DCP, which are not examined routinely in every part of the world. Therefore, the proposed classification should be further validated in other large study populations.     

An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma

BACKGROUND AND OBJECTIVES: Hepatocellular carcinoma (HCC) is a common cancer worldwide. As prognosis of HCC patients depends not only on tumour extension but also on liver function, TNM staging of HCC is of limited value. The Okuda score incorporating the variables of liver function and tumour extension is used widely. However, among patients with an intermediate Okuda score, survival varies considerably. Several newer scores promise to perform better than the Okuda score in stratifying HCC patients. We therefore tested the ability of several newer scores to predict survival in comparison to the Okuda score in a European cohort of HCC patients. PATIENTS AND METHODS: A total of 120 patients with sufficient follow-up data were identified retrospectively among the 130 patients with HCC first seen between 1997 and 2000 in our department. Child-Pugh score, Okuda score, Vienna survival model for HCC (VISUM-HCC) score, Chevret score, Barcelona clinic liver cancer (BCLC) classification and cancer of the liver Italian programme (CLIP) score were calculated. Survival analysis was performed for all eligible patients stratified according to each scoring system. Receiver operating characteristics analysis was performed using six months survival as the outcome measure. Univariate and stepwise logistic regression analyses were performed to identify prognostic factors. RESULTS: Survival times of HCC patients grouped according to all scores were significantly different. All scores performed similarly to the Okuda score in the receiver operating characteristic analysis. Prognostic factors for survival were albumin concentration and the presence of portal obstruction. CONCLUSION: In our central European cohort, there was no advantage of using the newer scores instead of the Okuda score.     

Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population

BACKGROUND: Median survival of patients with primary sclerosing cholangitis (PSC) has been estimated to be 12 years. Cholangiography is the gold standard for diagnosis but is rarely used in estimating prognosis. AIMS: To assess the natural history of Dutch PSC patients and to evaluate the prognostic value of a cholangiographic classification system. PATIENTS: A total of 174 patients with established PSC attending a university hospital and three teaching hospitals from 1970 to 1999. METHODS: Charts were reviewed for validity and time of diagnosis, concurrent inflammatory bowel disease, interventions, liver transplantation, occurrence of cholangiocarcinoma, and death. Follow up data were obtained from the charts and from the attending clinician or family physician. Median follow up was 76 months (range 1-300). The earliest available cholangiography was scored using a radiological classification system for the severity of sclerosis, developed in our institution. Survival curves were computed by the Kaplan-Meier method. Cholangiographic staging was used to construct a prognostic model, applying Cox proportional hazards analysis. RESULTS: The estimated median survival from time of diagnosis to death from liver disease or liver transplantation was 18 years. Cholangiocarcinoma was found in 18 (10%) patients. Fourteen patients (8%) underwent liver transplantation. Cholangiographic scoring was inversely correlated with survival. A combination of intrahepatic and extrahepatic scoring, together with age at endoscopic retrograde cholangiopancreatography, proved strongly predictive of survival. CONCLUSIONS: The observed survival was considerably better than reported in earlier series from Sweden, the UK, and the USA. Classification and staging of cholangiographic abnormalities has prognostic value.     

Comparison of prognostic scoring system to tumor node metastases 1992 and 1997 staging systems in gastric cancer patients

Tumor node metastases staging systems have been widely utilized to predict the prognosis of gastric cancer patients. The current study aimed to compare a prognostic scoring system to tumor node metastases 1992 and 1997 staging systems in predicting the outcome of resectable gastric cancer patients. Patients treated between 1996-1998 were retrospectively evaluated. Tumor depth in the gastric wall, anatomical location and number of metastatic lymph nodes, metastatic to retrieved lymph node ratio, extent of surgical resection, tumor location, type of lymph node dissection, macroscopic appearence and histologic type of tumor were recorded and patients were divided into groups I-III due to their scores. Patients were also staged according to both tumor node metastases systems. Survival data was analyzed by Kaplan-Meier method. For the comparison of power of the three systems in predicting survival, log-rank and Cox regression analysis were respectively used for univariate and multivariate analysis. 163 resectable gastric cancer patients were evaluated. Median follow-up and survival times were 26 and 23 months respectively. Overall 5-year survival was 37.6%. The number of patients in prognostic scoring groups I, II and III was 44, 109 and 10, respectively. According to tumor node metastases 1992 system, 13, 43, 101 and 6 patients were in stages I, II, III and IV while there were 13, 38, 78 and 34 patients in respective stages in tumor node metastases 1997 system. Although tumor node metastases 1992 (p=0.0088), 1997 (p=0.0029) and prognostic scoring systems (p=0.0006) significantly predicted the survival of patients in univariate analysis, prognostic scoring system was found to be superior compared to other two systems in multivariate analysis (p=0.0002). Prognostic scoring system is a practical, reliable and reproducible method that could be used as an adjunct to tumor node metastases systems in predicting survival of resectable gastric cancer patients.     

Staging in untreated patients with small cell lung cancer

In order to describe the real biological behavior of the small-cell lung cancer we have analyzed survival rates of 66 patients with small-cell lung cancer who did not receive any specific anti cancer therapy. Also, objective of this study was to evaluate the staging system of the small-cell lung cancer. Untreated small-cell lung cancer patients with limited stage disease had statistically significant (p < 0.05) better survival rates in comparison to patients with extensive stage disease. T and N factor of the TNM classification did not influence the survival in untreated small-cell lung cancer patients. It appears that the TNM staging system is not predicting survival probabilities of untreated patients with small-cell lung cancer, while the two-stage system appeared very well based on survival probabilities of these patients.     

Staging systems for pancreatic cancer: Differences between the Japanese and UICC systems

Differences between the clinical staging system of the Japan Pancreas Society (JPS) and the Union Internationale Contre le Cancer (UICC) stage classification may account for reported differences in the prognosis of pancreatic carcinoma between Japan and the West. In the review, we compared the characteristics of the JPS and UICC staging in 1689 patients, registered with the JPS from 1981 to 1990, who underwent resection for carcinoma of the pancreatic head. The survival rates correlated well with the JPS stage classification. The UICC staging did not reflect differences in prognoses among the stages. The current JPS staging system, introduced in 1993, still differs from that of the UICC. To compare the results of treatment for patients with pancreatic cancer it is important to establish a more practical and universal staging system for carcinoma of the pancreas.     

四种评分系统对失代偿期肝硬化患者短期预后的评价

目的比较终末期肝病模型(MELD))评分系统、MELD-Na评分系统、MESO指数评分系统以及iMELD评分系统对失代偿期肝硬化患者短期(3个月)预后的预测价值。方法选择2008年10月至2011年10月云南省第三人民医院消化内科的失代偿期肝硬化患者230例,分别计算每例患者入院时的MELD、MELD-Na、MESO及iMELD分值,采用Kaplan-Meier法比较生存率,运用受试者工作特征曲线(ROC)及曲线下面积(AUC)比较四种评分系统判断失代偿期肝硬化患者短期预后的价值。结果 230例失代偿期肝硬化患者,随访3个月内死亡68例,生存组MELD、MELD-Na、MESO及iMELD评分分别为22.34±4.36、24.26±5.45、1.62±0.23和37.59±6.97,死亡组MELD、MELD-Na、MESO及iMELD评分分别为27.76±5.28、30.11±6.19、2.05±0.1 8和46.65±7.01。死亡组与生存组的MELD、MELD)-Na、MESO及iMELD评分比较,差异均有统计学意义(P=0.005,0.005,0.000,0.003)。MELD、MELDNa、MESO及iMELD评分系统在判断230例失代偿期肝硬化患者3个月生存时间的ROC曲线下面积分别为0.852、0.856、0.857和0.847,95%可信区间分别为0.759～0.897、0.754～0.893、0.760～0.898、0.781～0.906,四种评分系统比较差异无统计学意义(P>0).05)。结论 MELD、MELD-Na、MESO及iMELD评分系统对失代偿期肝硬化患者短期预后均有一定的预测价值,但四种评分系统比较差异无统计学意义,较准确的预后判断仍需要结合临床实际。     

Reappraisal of the new UICC staging system for gastric cancer: problem in lymph node stage

BACKGROUND/AIMS: The International Union Against Cancer (UICC) TNM staging system defined a new system for classifying gastric cancer, based on the number of metastatic nodes (1997). However, the advantage of the new system is still a matter of debate. The aim of the present study is to compare the new system with the old one (1987), which is based on the location of positive lymph nodes. METHODOLOGY: We analyzed the survival of 608 patients with curative resection of their gastric cancer. The average number of resected and involved lymph nodes for each resected patient was 31.4 and 7.7. Comparison of these two systems was carried out to determine which classification was more effective. The prognostic value of different lymph node staging systems was also analyzed. RESULTS: One hundred and thirty-five patients (22.2%) had different N classification and 109 (17.9%) had different TNM staging. There was a significant stepwise decrease of slope of survival curve for each stage, but the new system did not cleanly separate stage II with IIIa at 3 years and stage IIIb with IV at 5 years. Although different lymph node staging systems were able to predict survival, the ratio rather than the number of involved nodes had a more cleanly separated stepwise decrease of slope of survival curve. CONCLUSIONS: The new UICC staging system is not better than the old system for the staging of gastric cancer. The reason is that the category of node number seems not to be appropriate and will be influenced by the extent of lymph node dissection. To overcome this problem, the frequency of involved nodes can be adopted instead of the number.     

Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score

The Japan Integrated Staging score (JIS score), which combines the Child-Turcotte-Pugh classification and tumor-node-metastasis staging, has been proposed as a better prognostic staging system for hepatocellular carcinoma (HCC) than the Cancer of the Liver Italian Program (CLIP) scoring system. In this study, validation was performed among a larger patient population. A total of 4,525 consecutive patients with HCC who had been diagnosed at five institutions were included. Stratification ability, prognostic predictive power, and reproducibility were analyzed and compared with results from the CLIP scoring system. Only 45% (1,951 of 4,525) of all patients were categorized as early stage HCC according to JIS score (0 or 1), whereas 63% (2,878 of 4,525) of the patients were categorized as having a CLIP score of 0 or 1. Significant differences in survival curves were not observed among CLIP scores 3 to 6. In contrast, survival curves showed significant differences among all the JIS scores. The same JIS scoring subgroups showed a similar prognosis, and good internal reproducibility was observed in each of the institutions. Multivariate analysis of the prognosis in all 4,525 patients proved the JIS score to be the best prognostic factor. Furthermore, the Akaike information criteria proved that the JIS scoring system was statistically a better model for predicting outcome than the CLIP scoring system. In conclusion, the stratification ability and prognostic predictive power of the JIS score were much better than that of the CLIP score and were simple to obtain and remember.